NBC’S STEPHANIE GOSK IN A MAJOR MOVE BY THE FDA AND EXPERIMENTAL
IN A MAJOR MOVE BY THE FDA AND EXPERIMENTAL NEW THERAPY AND WHEN
FDA AND EXPERIMENTAL NEW THERAPY AND WHEN VACCINE TRIALS COULD
NEW THERAPY AND WHEN VACCINE TRIALS COULD BEGIN.
VACCINE TRIALS COULD BEGIN. >> Reporter: TONIGHT,
BEGIN. >> Reporter: TONIGHT, NEWS ABOUT POTENTIALLY
>> Reporter: TONIGHT, NEWS ABOUT POTENTIALLY PROMISING, THOUGH SO
NEWS ABOUT POTENTIALLY PROMISING, THOUGH SO FAR SCIENTIFICALLY
PROMISING, THOUGH SO FAR SCIENTIFICALLY UNPROVEN DRUGS TO
FAR SCIENTIFICALLY UNPROVEN DRUGS TO COMBAT CORONAVIRUS.
UNPROVEN DRUGS TO COMBAT CORONAVIRUS. ON SUNDAY, THE FDA
COMBAT CORONAVIRUS. ON SUNDAY, THE FDA GIVING EMERGENCY
ON SUNDAY, THE FDA GIVING EMERGENCY AUTHORIZATION TO ADD
GIVING EMERGENCY AUTHORIZATION TO ADD TWO ANTI MALARIA
AUTHORIZATION TO ADD TWO ANTI MALARIA MEDICATIONS TO THE
TWO ANTI MALARIA MEDICATIONS TO THE NATIONAL STOCKPILE.
MEDICATIONS TO THE NATIONAL STOCKPILE. CHLOROQUINE AND
NATIONAL STOCKPILE. CHLOROQUINE AND HYDROXYCHLOROQUINE.
CHLOROQUINE AND HYDROXYCHLOROQUINE. HOSPITALS AND DOCTORS
HYDROXYCHLOROQUINE. HOSPITALS AND DOCTORS HAVE BEEN PRESCRIBING
HOSPITALS AND DOCTORS HAVE BEEN PRESCRIBING THE MEDICATION WITH
HAVE BEEN PRESCRIBING THE MEDICATION WITH CLINICAL TRIALS
THE MEDICATION WITH CLINICAL TRIALS UNDERWAY IN NEW YORK
CLINICAL TRIALS UNDERWAY IN NEW YORK AND MINNESOTA.
UNDERWAY IN NEW YORK AND MINNESOTA. JAMES WHO IS STILL IN
AND MINNESOTA. JAMES WHO IS STILL IN THE HOSPITAL STARTED
JAMES WHO IS STILL IN THE HOSPITAL STARTED TREATMENTS LAST WEEK.
THE HOSPITAL STARTED TREATMENTS LAST WEEK. >> THURSDAY MORNING I
TREATMENTS LAST WEEK. >> THURSDAY MORNING I WAS AT MILOY LOW POINT.
>> THURSDAY MORNING I WAS AT MILOY LOW POINT. THAT’S WHEN I THOUGHT
WAS AT MILOY LOW POINT. THAT’S WHEN I THOUGHT I WAS GOING TO DIE.
THAT’S WHEN I THOUGHT I WAS GOING TO DIE. >> Reporter: THAT DAY
I WAS GOING TO DIE. >> Reporter: THAT DAY DOCTORS GAVE HIM
>> Reporter: THAT DAY DOCTORS GAVE HIM HYDROXYCHLOROQUINE.
DOCTORS GAVE HIM HYDROXYCHLOROQUINE. >> I WOKE UP AT
HYDROXYCHLOROQUINE. >> I WOKE UP AT MIDNIGHT FEELING
>> I WOKE UP AT MIDNIGHT FEELING DIFFERENT.
MIDNIGHT FEELING DIFFERENT. I FELT LIKE ALL RIGHT,
DIFFERENT. I FELT LIKE ALL RIGHT, THE BODY ISN’T HURTING
I FELT LIKE ALL RIGHT, THE BODY ISN’T HURTING SO MUFFCH, I’M NOT
THE BODY ISN’T HURTING SO MUFFCH, I’M NOT COUGHING SO MUCH.
SO MUFFCH, I’M NOT COUGHING SO MUCH. >> Reporter: SO FAR
COUGHING SO MUCH. >> Reporter: SO FAR THERE IS NO CLINICAL
>> Reporter: SO FAR THERE IS NO CLINICAL PROOF THE ANTI MALARIA
THERE IS NO CLINICAL PROOF THE ANTI MALARIA DRUG WORKS BUT THE FDA
PROOF THE ANTI MALARIA DRUG WORKS BUT THE FDA SAYS IT’S WORTH TO THE
DRUG WORKS BUT THE FDA SAYS IT’S WORTH TO THE RISK TO USE THEM WITH
SAYS IT’S WORTH TO THE RISK TO USE THEM WITH PATIENTS IN SERIOUS
RISK TO USE THEM WITH PATIENTS IN SERIOUS CONDITION.
PATIENTS IN SERIOUS CONDITION. THEY ARE ALSO CHANCE
CONDITION. THEY ARE ALSO CHANCE TRANSFUSING PLASMA.
THEY ARE ALSO CHANCE TRANSFUSING PLASMA. >> THE IDEA THAT
TRANSFUSING PLASMA. >> THE IDEA THAT PLASMA MAY HAVE PARTS
>> THE IDEA THAT PLASMA MAY HAVE PARTS OF THE IMMUNE SYSTEM
PLASMA MAY HAVE PARTS OF THE IMMUNE SYSTEM LIKE ANTIBODIES
OF THE IMMUNE SYSTEM LIKE ANTIBODIES AGAINST THE COVID-19
LIKE ANTIBODIES AGAINST THE COVID-19 VIRUS THAT COULD
AGAINST THE COVID-19 VIRUS THAT COULD POTENTIALLY HELP
VIRUS THAT COULD POTENTIALLY HELP PATIENTS.
POTENTIALLY HELP PATIENTS. >> Reporter: BUT THE
PATIENTS. >> Reporter: BUT THE MOST LONG-TERM HOPE IS
>> Reporter: BUT THE MOST LONG-TERM HOPE IS BEING PLACED IN THE
MOST LONG-TERM HOPE IS BEING PLACED IN THE DEVELOPMENT OF A
BEING PLACED IN THE DEVELOPMENT OF A VACCINE.
DEVELOPMENT OF A VACCINE. TODAY, JOHNSON &amp;
VACCINE. TODAY, JOHNSON &amp; JOHNSON SAYS IT HAS A
TODAY, JOHNSON &amp; JOHNSON SAYS IT HAS A PROMISING POSSIBILITY.
JOHNSON SAYS IT HAS A PROMISING POSSIBILITY. >> THIS IS LIKE A MOON
PROMISING POSSIBILITY. >> THIS IS LIKE A MOON SHOT FOR US AT JOHNSON
>> THIS IS LIKE A MOON SHOT FOR US AT JOHNSON &amp; JOHNSON.
SHOT FOR US AT JOHNSON &amp; JOHNSON. WHAT WOULD USUALLY
&amp; JOHNSON. WHAT WOULD USUALLY TAKE FIVE IS SEVEN
WHAT WOULD USUALLY TAKE FIVE IS SEVEN YEARS WE EXPECT TO
TAKE FIVE IS SEVEN YEARS WE EXPECT TO ACCOMPLISH IN FIVE TO
YEARS WE EXPECT TO ACCOMPLISH IN FIVE TO SEVEN MONTHS.
ACCOMPLISH IN FIVE TO SEVEN MONTHS. >> JOHNSON &amp; JOHNSON’S
SEVEN MONTHS. >> JOHNSON &amp; JOHNSON’S POSSIBLE VACCINE WILL
>> JOHNSON &amp; JOHNSON’S POSSIBLE VACCINE WILL GO THROUGH RIGOROUS
POSSIBLE VACCINE WILL GO THROUGH RIGOROUS TRIALS BUT IT SAYS IN
GO THROUGH RIGOROUS TRIALS BUT IT SAYS IN THE COMING DAYS IT
